Skip to main content

Advertisement

SpringerLink
Log in

Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part I

  • Review
  • Published:
Archivum Immunologiae et Therapiae Experimentalis Aims and scope

Abstract

The process of chronic inflammation is a common link which connects different kinds of environmental pollutants and infections with tumorigenesis. Transcription factor NF-κB is a common final target for many inflammatory and cell proliferation pathways, independent of the source of stimuli (e.g., cytokines, growth factors, environmental carcinogens, radiation, hypoxia, bacteria, and viruses). Over-activation of NF-κB has been confirmed in many tumors, resulting in worse prognosis for patient survival. Therefore, inhibition of cellular pathways for NF-κB activation is nowadays considered as a promising anti-cancer therapy and is extensively studied in clinical trials, or even has been adopted as an approved therapy in some kinds of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

Akt:

Serine/threonine protein kinase

cIAP2:

Inhibitor of apoptosis protein 2

COX-2:

Cyclooxygenase-2

CTR1:

Copper transporter-1

CXCL:

CXC motif chemokine ligand

HIF:

Hypoxia-inducible factor

HSF1:

Heat shock factor-1

HSR:

Heat shock response

ICAM-1:

Intercellular adheson molecule-1

IKK:

IκB kinase

IκB:

Inhibitor of NF-κB

MALT1:

Mucosa-associated lymphoid tissue lymphoma translocation protein 1

MMP:

Matrix metalloproteinase

NEMO:

NF-κB essential modulator

NF-κB:

Nuclear factor κB

NIK:

NF-κB-inducing kinase

NSAIDs:

Non-steroid anti-inflammatory drugs

PGE2 :

Prostaglandin E2

PI3K:

Phosphatidylinositol 3-kinase

STAT-3:

Signal transducer and activator of transcription 3

TAK1:

Transforming growth factor-β-activated kinase-1

TNF:

Tumor necrosis factor

TRAF:

TNF receptor-associated factor

TRAIL:

TNF-related apoptosis-inducing ligand

VEGF:

Vascular-endothelial growth factor

References

  • Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203–208

    Article  PubMed  CAS  Google Scholar 

  • Aggarwal S, Ichikawa H, Takada Y et al (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and akt activation. Mol Pharmacol 69:195–206

    PubMed  CAS  Google Scholar 

  • Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15:425–430

    Article  PubMed  CAS  Google Scholar 

  • Ahn KS, Sethi G, Aggarwal BB (2007) Nuclear factor-kappaB: from clone to clinic. Curr Mol Med 7:619–637

    Article  PubMed  CAS  Google Scholar 

  • Anderson KN, Bejcek BE (2008) Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB. J Pharmacol Sci 106:318–320

    Article  PubMed  CAS  Google Scholar 

  • Annunziata CM, Davis RE, Demchenko Y et al (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115–130

    Article  PubMed  CAS  Google Scholar 

  • Antony B, Merina B, Iyer VS et al (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70:445–449

    Article  PubMed  CAS  Google Scholar 

  • Aragon-Ching JB, Li H, Gardner ER et al (2007) Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov 2:167–174

    Article  PubMed  CAS  Google Scholar 

  • Awada A, Albanell J, Canney PA et al (2008) Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 98:1500–1507

    Article  PubMed  CAS  Google Scholar 

  • Bachmeier BE, Mohrenz IV, Mirisola V et al (2008) Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 29:779–789

    Article  PubMed  CAS  Google Scholar 

  • Bassères DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817–6830

    Article  PubMed  CAS  Google Scholar 

  • Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33–40

    Article  PubMed  CAS  Google Scholar 

  • Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274:782–784

    Article  PubMed  CAS  Google Scholar 

  • Berenson J, Yang H, Swift R et al (2004) A Phase I/II trial of VELCADE and melphalan combination therapy (Vc + M) for patients with relapsed or refractory multiple myeloma (MM). Blood 104:164a

    Google Scholar 

  • Birle DC, Hedley DW (2007) Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 67:1735–1743

    Article  PubMed  CAS  Google Scholar 

  • Bork PM, Schmitz ML, Kuhnt M et al (1997) Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402:85–90

    Article  PubMed  CAS  Google Scholar 

  • Boyar MS, Hesdorffer M, Keohan ML et al (2008) Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. Sarcoma 2008:412503

    Article  PubMed  CAS  Google Scholar 

  • Chen YC, Shen SC, Lee WR et al (2002) Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76:351–359

    Article  PubMed  CAS  Google Scholar 

  • Cohen AN, Veena MS, Srivatsan ES et al (2009) Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg 135:190–197

    Article  PubMed  Google Scholar 

  • Culver C, Sundqvist A, Mudie S et al (2010) Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol 30:4901–4921

    Article  PubMed  CAS  Google Scholar 

  • Czyz M, Lesiak-Mieczkowska K, Koprowska K et al (2010) Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol 160:1144–1157

    Article  PubMed  CAS  Google Scholar 

  • D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085

    Article  PubMed  Google Scholar 

  • Dahut WL, Aragon-Ching JB, Woo S et al (2009) A phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49:650–660

    Article  PubMed  CAS  Google Scholar 

  • Davies AM, Chansky K, Jr1 Lara PN et al (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group study (S0339). J Thorac Oncol 4:87–92

    Article  PubMed  Google Scholar 

  • Davis NB, Taber DA, Ansari RH et al (2004) Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago Phase II consortium study. J Clin Oncol 22:115–119

    Article  PubMed  CAS  Google Scholar 

  • Denlinger CE, Rundall BK, Keller MD et al (2004) Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78:1207–1214

    Article  PubMed  Google Scholar 

  • Dey A, Wong ET, Cheok CF et al (2008) R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 15:263–273

    Article  PubMed  CAS  Google Scholar 

  • Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–4499

    Article  PubMed  CAS  Google Scholar 

  • Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117:508–515

    Article  PubMed  CAS  Google Scholar 

  • Din FVN, Dunlop MG, Stark LA (2004) Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis. Br J Cancer 91:381–388

    PubMed  CAS  Google Scholar 

  • Din FV, Stark LA, Dunlop MG (2005) Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. Br J Cancer 92:1137–1143

    Article  PubMed  CAS  Google Scholar 

  • Dredge K, Marriott JB, Todryk SM et al (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914–4919

    PubMed  CAS  Google Scholar 

  • Duechler M, Stańczyk M, Czyz M et al. (2008) Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. Cancer Chemother Pharmacol 61:727–237

    Google Scholar 

  • Dy GK, Thomas JP, Wilding G et al (2005) A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11:3410–3416

    Article  PubMed  CAS  Google Scholar 

  • Fan Y, Dutta J, Gupta N et al (2008) Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615:223–250

    Article  PubMed  CAS  Google Scholar 

  • Fei XF, Wang BX, Li TJ et al (2003) Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94:92–98

    Article  PubMed  CAS  Google Scholar 

  • Figg WD, Dahut W, Duray P et al (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888–1893

    PubMed  CAS  Google Scholar 

  • Fleming IN, Hogben M, Frame S et al (2008) Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 14:4326–4335

    Article  PubMed  CAS  Google Scholar 

  • Frankel A, Man S, Elliott P et al (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719–3728

    PubMed  CAS  Google Scholar 

  • Frelin C, Imbert V, Griessinger E et al (2005) Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105:804–811

    Article  PubMed  CAS  Google Scholar 

  • Fujita J, Mestre JR, Zeldis JB et al (2001) Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 7:3349–3355

    PubMed  CAS  Google Scholar 

  • García MG, Alaniz L, Lopes EC et al (2005) Inhibition of NF-kappaB activity by BAY 11–7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 29:1425–1434

    Article  PubMed  CAS  Google Scholar 

  • García-Piñeres AJ, Castro V, Mora G et al (2001) Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276:39713–39720

    Article  PubMed  CAS  Google Scholar 

  • Gasparian AV, Guryanova OA, Chebotaev DV et al (2009) Targeting transcription factor NF-kappaB. Cell Cycle 8:1559–1566

    Article  PubMed  CAS  Google Scholar 

  • Gatto S, Scappini B, Pham L et al (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Ablpositive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88:853–863

    PubMed  CAS  Google Scholar 

  • Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8:837–848

    Article  PubMed  CAS  Google Scholar 

  • Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(suppl):S81–S96

    Article  PubMed  CAS  Google Scholar 

  • Gilmore TD, Herscovitch M (2006) Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25:6887–6899

    Article  PubMed  CAS  Google Scholar 

  • Gordon JN, Trebble TM, Ellis RD et al (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54:540–545

    Article  PubMed  CAS  Google Scholar 

  • Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950–1961

    PubMed  CAS  Google Scholar 

  • Gurova K (2009) New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol 5:1685–1713

    Article  PubMed  CAS  Google Scholar 

  • Gurova KV, Hill JE, Guo C et al (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102:17448–17453

    Article  PubMed  CAS  Google Scholar 

  • Guzman ML, Rossi RM, Karnischky L et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163–4169

    Article  PubMed  CAS  Google Scholar 

  • Haddad AQ, Venkateswaran V, Viswanathan L et al (2006) Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9:68–76

    Article  PubMed  CAS  Google Scholar 

  • Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076

    PubMed  CAS  Google Scholar 

  • Hideshima T, Ikeda H, Chauhan D et al (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114:1046–1052

    Article  PubMed  CAS  Google Scholar 

  • Hill DS, Martin S, Armstrong JL et al (2009) Combining the ER-stress inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma. Clin Cancer Res 15:1192–1198

    Article  PubMed  CAS  Google Scholar 

  • Höpfner M, Schuppan D, Scherübl H (2008) Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1–14

    Article  PubMed  CAS  Google Scholar 

  • Israël A (2010) The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2:a000158

    Article  PubMed  CAS  Google Scholar 

  • Jagannath S, Wolf JL, Camacho E et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776–783

    Article  PubMed  CAS  Google Scholar 

  • Jandial DD, Farshchi-Heydari S, Larson CA et al (2009) Enhanced delivery of cisplatin to intraperitoneal ovariancarcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15:553–560

    Article  PubMed  CAS  Google Scholar 

  • Karin M (2008) The IkappaB kinase––a bridge between inflammation and cancer. Cell Res 18:334–342

    Article  PubMed  CAS  Google Scholar 

  • Keifer JA, Guttridge DC, Ashburner BP et al (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382–22387

    Article  PubMed  CAS  Google Scholar 

  • Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188–1192

    Article  PubMed  CAS  Google Scholar 

  • Kondagunta GV, Drucker B, Schwartz L et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720–3725

    Article  PubMed  CAS  Google Scholar 

  • Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36–46

    Article  PubMed  CAS  Google Scholar 

  • Kraemer A, Hauser S, Kim Y et al. (2009) Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger Med Sci 7:Doc04

    Google Scholar 

  • Kubicek GI, Werner-Wasik M, Machtay M et al (2009) A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for CNS malignancies. Int J Radiat Oncol Biol Phys 74:433–439

    Article  PubMed  CAS  Google Scholar 

  • Kunnumakkara AB, Ichikawa H, Anand P et al (2008) Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappaB pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis. Mol Cancer Ther 7:3306–3317

    Article  PubMed  CAS  Google Scholar 

  • LeBlanc R, Catley LP, Hideshima T et al (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996–5000

    PubMed  CAS  Google Scholar 

  • Lee CH, Jeon YT, Kim SH et al (2007) NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29:19–35

    Article  PubMed  CAS  Google Scholar 

  • Li J, Cheng Y, Qu W (2011) Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 108:84–93

    Article  PubMed  CAS  Google Scholar 

  • Lieu C, Chow L, Pierson AS et al (2009) A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 27:53–62

    Article  PubMed  CAS  Google Scholar 

  • Lilenbaum R, Wang X, Gu L et al (2009) Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 27:4487–4491

    Article  PubMed  CAS  Google Scholar 

  • Lu X, Jung J, Cho HJ et al (2005) Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 135:2884–2890

    PubMed  CAS  Google Scholar 

  • Ludwig H, Khayat D, Giaccone G et al (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794–1807

    Article  PubMed  CAS  Google Scholar 

  • Luo JL, Kamata H, Karin M (2005) IKK/NF-kappaB signaling: balancing life and death––a new approach to cancer therapy. J Clin Invest 115:2625–2632

    Article  PubMed  CAS  Google Scholar 

  • McMeekin DS, Sill MW, Benbrook D et al (2007) A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group Study. Gynecol Oncol 105:508–516

    Article  PubMed  CAS  Google Scholar 

  • Menéndez S, Higgins M, Berkson RG et al (2003) Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. Br J Cancer 88:636–643

    Article  PubMed  CAS  Google Scholar 

  • Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525–4530

    Article  PubMed  CAS  Google Scholar 

  • Mitsiades CS, McMillin D, Kotoula V et al (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91:4013–4021

    Article  PubMed  CAS  Google Scholar 

  • Mitsiades CS, Hideshima T, Chauhan D et al (2009) Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib. Semin Hematol 46:166–175

    Article  PubMed  CAS  Google Scholar 

  • Mulligan G, Mitsiades C, Bryant B et al (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109:3177–3188

    Article  PubMed  CAS  Google Scholar 

  • Mutka SC, Yang WQ, Dong SD et al (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510–517

    Article  PubMed  CAS  Google Scholar 

  • Naugler WE, Karin M (2008) NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18:19–26

    Article  PubMed  CAS  Google Scholar 

  • Neznanov N, Gorbachev AV, Neznanova L et al (2009) Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8:3960–3970

    Article  PubMed  CAS  Google Scholar 

  • O’Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol 23:676–684

    Article  PubMed  CAS  Google Scholar 

  • O’Neil BH, Raftery L, Calvo BF et al (2010) A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer 9:119–125

    Article  PubMed  CAS  Google Scholar 

  • Orlowski RZ, Voorhees PM, Garcia RA et al (2005) Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058–3065

    Article  PubMed  CAS  Google Scholar 

  • Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853–6866

    Article  PubMed  CAS  Google Scholar 

  • Perkins ND (2004) NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14:64–69

    Article  PubMed  CAS  Google Scholar 

  • Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466

    Article  PubMed  CAS  Google Scholar 

  • Puduvalli VK, Giglio P, Groves MD et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10:216–222

    Article  PubMed  CAS  Google Scholar 

  • Ramsay AG, Gribben JG (2009) Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 94:1198–1202

    Article  PubMed  CAS  Google Scholar 

  • Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11:495–510

    Article  PubMed  CAS  Google Scholar 

  • Richardson PG, Chanan-Khan A, Schlossman RL et al (2004) Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma (MM). Blood 104:100a

    Article  CAS  Google Scholar 

  • Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458–3464

    Article  PubMed  CAS  Google Scholar 

  • Robe PA, Bentires-Alj M, Bonif M et al (2004) In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10:5595–5603

    Article  PubMed  CAS  Google Scholar 

  • Roberts BJ, Hamelehle KL, Sebolt JS et al (1986) In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114, 721). Cancer Chemother Pharmacol 16:95–101

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez MS, Thompson J, Hay RT et al (1999) Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem 274:9108–9115

    Article  PubMed  CAS  Google Scholar 

  • Saadane A, Masters S, DiDonato J et al (2007) Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 36:728–736

    Article  PubMed  CAS  Google Scholar 

  • Scheidereit C (2006) IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25:6685–6705

    Article  PubMed  CAS  Google Scholar 

  • Schönthal AH (2007) Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 97:1465–1468

    Article  PubMed  CAS  Google Scholar 

  • Scortegagna M, Cataisson C, Martin RJ et al (2008) HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 111:3343–3354

    Article  PubMed  CAS  Google Scholar 

  • Sethi G, Ahn KS, Sung B et al (2008a) Pinitol targets nuclear factor-κB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther 7:1604–1614

    Article  PubMed  CAS  Google Scholar 

  • Sethi G, Sung B, Aggarwal BB (2008b) Nuclear factor-κB activation: from bench to bedside. Exp Biol Med 233:21–31

    Article  CAS  Google Scholar 

  • Shankar S, Ganapathy S, Chen Q et al (2008) Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7:16–29

    Article  PubMed  CAS  Google Scholar 

  • Shen RR, Hahn WC (2011) Emerging roles for the non-canonical IKKs in cancer. Oncogene 30:631–641

    Article  PubMed  CAS  Google Scholar 

  • Shishodia S, Aggarwal BB (2004) Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol 68:1071–1080

    Article  PubMed  CAS  Google Scholar 

  • Shishodia S, Koul D, Aggarwal BB (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NFkappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173:2011–2022

    PubMed  CAS  Google Scholar 

  • Sung B, Pandey MK, Aggarwal BB (2007) Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 71:1703–1714

    Article  PubMed  CAS  Google Scholar 

  • Sung B, Kunnumakkara AB, Sethi G et al (2009) Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8:959–970

    Article  PubMed  CAS  Google Scholar 

  • Swamy MV, Herzog CR, Rao CV (2003) Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 63:5239–5242

    PubMed  CAS  Google Scholar 

  • Takada Y, Aggarwal BB (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279:4750–4759

    Article  PubMed  CAS  Google Scholar 

  • Takada Y, Bhardwaj A, Potdar P et al (2004) Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23:9247–9258

    PubMed  CAS  Google Scholar 

  • Takada Y, Kobayashi Y, Aggarwal BB (2005) Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IκBα kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 280:17203–17212

    Article  PubMed  CAS  Google Scholar 

  • Tergaonkar V, Correa RG, Ikawa M et al (2005) Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity. Nat Cell Biol 7:921–923

    Article  PubMed  CAS  Google Scholar 

  • Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115–122

    Article  PubMed  CAS  Google Scholar 

  • Wang D, Veena MS, Stevenson K et al (2008) Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin Cancer Res 14:6228–6236

    Article  PubMed  CAS  Google Scholar 

  • Wen J, You KR, Lee SY et al (2002) Oxidative stress-mediated apoptosis the anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277:38954–38964

    Article  PubMed  CAS  Google Scholar 

  • Wilczynski JR, Duechler M (2010) Immunotherapy for epithelial ovarian cancer––immunological background, critical review of methods and future perspectives. Curr Immunol Rev 6:221–223

    Article  CAS  Google Scholar 

  • Williams S, Pettaway C, Song R et al (2003) Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2:835–843

    PubMed  CAS  Google Scholar 

  • Zangari M, Barlogie B, Hollmig K et al (2004) Marked activity of Velcade plus thalidomide (V + T) in advanced and refractory multiple myeloma (MM). Blood 104:413a–414a

    Google Scholar 

  • Zhou J, Zhang H, Gu P et al (2008) NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111:419–427

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The work was supported by the grant no. N402 458738 from the Ministry of Science and Higher Education (Poland).

Author information

Authors and Affiliations

  1. “Polish Mother’s Health Center” Research Institute, Rzgowska 281/289, 93-338, Lodz, Poland

    Jacek Wilczynski

  2. Department of Gynecology, Medical University of Lodz, Lodz, Poland

    Jacek Wilczynski

  3. Department of Bioorganic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Lodz, Poland

    Markus Duechler

  4. Department of Molecular Biology of Cancer, Medical University of Lodz, Lodz, Poland

    Malgorzata Czyz

Authors
  1. Jacek Wilczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Duechler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Malgorzata Czyz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacek Wilczynski.

About this article

Cite this article

Wilczynski, J., Duechler, M. & Czyz, M. Targeting NF-κB and HIF-1 Pathways for the Treatment of Cancer: Part I. Arch. Immunol. Ther. Exp. 59, 289–299 (2011). https://doi.org/10.1007/s00005-011-0131-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00005-011-0131-4

Keywords

Search

Navigation